Brad Knott Stock Trades

Brad Knott Trading Profile | Quantellect Brad Knott Trading Profile

Brad Knott's disclosure record covers exactly three transactions, all from a narrow span of trading activity in January 2025, and all attributed to the North Carolina Republican himself. The House member, who represents the state's 13th district and took office at the start of the current term, had disclosed no later transaction as of August 21, 2026. That narrow window is the entire record in the dataset so far, and it says more about disclosure timing than about an active trading habit.

The three transactions involve two companies. Knott purchased CompoSecure, Inc. (CMPO) twice, on January 10 and January 14, 2025, each in the disclosed $1,001 to $15,000 range. On the same day as the first CompoSecure purchase, he also sold Oramed Pharmaceuticals Inc. (ORMP), in the disclosed $15,001 to $50,000 range. All three transactions were disclosed together on February 25, 2025.

A concentrated, short-lived cluster

Knott's only recorded activity occurred between January 10 and January 14, 2025. Of the three transactions, two were purchases and one was a sale. Because this is the only period in the record, it is not possible to describe a pattern over time or a shift in behavior. What can be said is that the activity was concentrated rather than spread out, and that it touched only two companies across two different sectors.

The CompoSecure purchases account for two of the three transactions and make it the most frequently disclosed security in Knott's record. CompoSecure, Inc. designs and manufactures metal, composite, and proprietary financial transaction cards. Its payment-card technology and metal cards include Arculus secure-authentication and digital-asset-storage capabilities. The company serves primarily financial institutions, plastic card manufacturers, system integrators, and security specialists. It is classified in the Industrials sector under the Machinery industry group. Founded in 2000 and based in Somerset, New Jersey, CompoSecure sits at an intersection of physical card manufacturing, secure authentication, and access to financial and digital assets.

The lone sale was Oramed Pharmaceuticals Inc., a pharmaceutical company engaged in researching and developing oral-delivery technology for therapeutic proteins. It develops ORMD-0801, an oral insulin capsule in Phase III trials for the treatment of people with diabetes. Oramed also has license agreements with Oravax Medical Inc. related to commercializing oral vaccines for COVID-19. It is classified in the Health Care sector under Pharmaceuticals. The company was incorporated in 2002 and is headquartered in New York.

Taken together, the two sector tags in Knott's record, Industrials and Health Care, do not point to an obvious thematic tilt. One purchase-heavy name in payment-card and authentication technology, and one sale in clinical-stage pharmaceuticals, is too small a sample to characterize as a strategy or a sector preference. It is simply what has been disclosed.

Score context and disclosure landscape

Knott's associated score sits at 28, placing him in a "mixed" tier as of August 21, 2026. That score carries a "thin" coverage designation and ranks him 56th within a 76-member cohort. A population snapshot dated August 22, 2026, lists 537 sitting members of Congress: 437 in the House and 100 in the Senate. Of those members, 276 had zero disclosed transactions in the dataset, including 237 House members and 39 senators. Scores were available for 76 members overall, 73 of whom were sitting members.

Disclosure and methodology notes

The transaction data on this page is drawn from Knott's official financial disclosure filing with the House Clerk's office. The filing was submitted under the requirements of the Stop Trading on Congressional Knowledge Act of 2012. Under the House Committee on Ethics financial disclosure instruction guide, covered securities transactions over $1,000 must be reported by the earlier of 30 days after the filer becomes aware of the transaction or 45 days after the transaction date. All three transactions in this record are attributed to Knott personally, with no spousal, dependent, joint, or unknown attribution codes present.

This profile is limited to disclosed transaction events. Periodic transaction reports record purchases, sales, dates, and disclosed value ranges rather than providing a continuing account snapshot. For readers tracking this profile going forward, the relevant signal will be whether additional periodic transaction reports appear beyond the January 2025 cluster, and whether any new activity broadens the sector footprint beyond payment technology and pharmaceuticals.